Literature DB >> 2470922

Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function.

J A Beeler1, K van Wyke Coelingh.   

Abstract

Eighteen neutralizing monoclonal antibodies (MAbs) specific for the fusion glycoprotein of the A2 strain of respiratory syncytial virus (RSV) were used to construct a detailed topological and operational map of epitopes involved in neutralization and fusion. Competitive binding assays identified three nonoverlapping antigenic sites (A, B, and C) and one bridge site (AB). Thirteen MAb-resistant mutants (MARMs) were selected, and the neutralization patterns of the MAbs with either MARMs or RSV clinical strains identified a minimum of 16 epitopes. MARMs selected with antibodies to six of the site A and AB epitopes displayed a small-plaque phenotype, which is consistent with an alteration in a biologically active region of the F molecule. Analysis of MARMs also indicated that these neutralization epitopes occupy topographically distinct but conformationally interdependent regions with unique biological and immunological properties. Antigenic variation in F epitopes was examined by using 23 clinical isolates (18 subgroup A and 5 subgroup B) in cross-neutralization assays with the 18 anti-F MAbs. This analysis identified constant, variable, and hypervariable regions on the molecule and indicated that antigenic variation in the neutralization epitopes of the RSV F glycoprotein is the result of a noncumulative genetic heterogeneity. Of the 16 eptiopes, 8 were conserved on all or all but 1 of 23 subgroup A or subgroup B clinical isolates.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470922      PMCID: PMC250848     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies.

Authors:  E E Walsh; P J Cote; B F Fernie; J J Schlesinger; M W Brandriss
Journal:  J Gen Virol       Date:  1986-03       Impact factor: 3.891

2.  The fusion glycoprotein of Sendai virus: sequence analysis of an epitope involved in fusion and virus neutralization.

Authors:  A Portner; R A Scroggs; C W Naeve
Journal:  Virology       Date:  1987-04       Impact factor: 3.616

3.  Monoclonal antibodies specific for Sendai virus. I. Production and characterization of monoclonal antibodies.

Authors:  M Fenner; H Binz
Journal:  Scand J Immunol       Date:  1986-09       Impact factor: 3.487

4.  Protease activation mutants of Sendai virus: sequence analysis of the mRNA of the fusion protein (F) gene and direct identification of the cleavage-activation site.

Authors:  M C Hsu; A Scheid; P W Choppin
Journal:  Virology       Date:  1987-01       Impact factor: 3.616

5.  Antigenic mapping and functional analysis of the F protein of Newcastle disease virus using monoclonal antibodies.

Authors:  G Abenes; H Kida; R Yanagawa
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

6.  Antigenic variation between human respiratory syncytial virus isolates.

Authors:  H B Gimenez; N Hardman; H M Keir; P Cash
Journal:  J Gen Virol       Date:  1986-05       Impact factor: 3.891

7.  Heterogeneity of the respiratory syncytial virus 22K protein revealed by Western blotting with monoclonal antibodies.

Authors:  E G Routledge; M M Willcocks; L Morgan; A C Samson; R Scott; G L Toms
Journal:  J Gen Virol       Date:  1987-04       Impact factor: 3.891

8.  Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity.

Authors:  R A Olmsted; N Elango; G A Prince; B R Murphy; P R Johnson; B Moss; R M Chanock; P L Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

9.  Occurrence of respiratory syncytial virus subtypes A and B strains in Sweden.

Authors:  B Akerlind; E Norrby
Journal:  J Med Virol       Date:  1986-07       Impact factor: 2.327

10.  Comparative analyses of the specificities of anti-influenza hemagglutinin antibodies in human sera.

Authors:  M L Wang; J J Skehel; D C Wiley
Journal:  J Virol       Date:  1986-01       Impact factor: 5.103

View more
  124 in total

1.  Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein.

Authors:  Margarita Magro; David Andreu; Paulino Gómez-Puertas; José A Melero; Concepción Palomo
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

2.  Future opportunities for passive immunity against viral diseases.

Authors:  Barney S Graham
Journal:  J Infect Dis       Date:  2011-10-12       Impact factor: 5.226

Review 3.  Neutralizing epitopes of RSV and palivizumab resistance in Japan.

Authors:  Koichi Hashimoto; Mitsuaki Hosoya
Journal:  Fukushima J Med Sci       Date:  2017-09-01

4.  Amino acid variation within the fusion protein of respiratory syncytial virus subtype A and B strains during annual epidemics in South Africa.

Authors:  Elizabeth Agenbach; Caroline T Tiemessen; Marietjie Venter
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

5.  Complete sequence of the RNA genome of pneumonia virus of mice (PVM).

Authors:  Christine D Krempl; Elaine W Lamirande; Peter L Collins
Journal:  Virus Genes       Date:  2005-03       Impact factor: 2.332

6.  Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.

Authors:  Eileen Goodwin; Morgan S A Gilman; Daniel Wrapp; Man Chen; Joan O Ngwuta; Syed M Moin; Patricia Bai; Arvind Sivasubramanian; Ruth I Connor; Peter F Wright; Barney S Graham; Jason S McLellan; Laura M Walker
Journal:  Immunity       Date:  2018-02-03       Impact factor: 31.745

7.  Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity.

Authors:  Roderick S Tang; Jeanne H Schickli; Mia MacPhail; Fiona Fernandes; Leenas Bicha; Joshua Spaete; Ron A M Fouchier; Albert D M E Osterhaus; Richard Spaete; Aurelia A Haller
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 8.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

9.  Antigenic analysis of the F protein of the bovine respiratory syncytial virus: identification of two distinct antigenic sites involved in fusion inhibition.

Authors:  J P Matheise; K Walravens; A Collard; P Coppe; J J Letesson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

Review 10.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.